Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Terns Pharmaceuticals, Inc. - Common Stock (NQ:TERN)

52.72 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	0
Open	-
Bid (Size)	52.58 (200)
Ask (Size)	52.79 (100)
Prev. Close	52.72
Today's Range	52.72 - 52.72
52wk Range	1.865 - 53.19
Shares Outstanding	61,071,897
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

April 02, 2026

From Terns Pharmaceuticals, Inc.

Via GlobeNewswire

ARM Makes Its Move While Wall Street Watches the Strait ↗

March 26, 2026

Via Chartmill

Performance

YTD	+31.4%	+31.4%
1 Month	+25.5%	+25.5%
3 Month	+34.5%	+34.5%
6 Month	+525.4%	+525.4%
1 Year	+2410.5%	+2410.5%

More News

Terns Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Terns Pharmaceuticals, Inc. - TERN

March 25, 2026

From Kahn Swick & Foti, LLC

Via Business Wire

The Strategic Renaissance: Why 2026 is the Year of the Takeover Tailwind

March 25, 2026

Via MarketMinute

VKTX, TERN, GPCR Shares Rally As Novo Nordisk Sounds Willingness Towards Portfolio-Expansion Deals ↗

January 14, 2026

Via Stocktwits

The $6.7 Billion Pivot: A Deep Dive into Terns Pharmaceuticals (TERN) and the Merck Acquisition

March 25, 2026

Via Finterra

TERN Stock Alert: Halper Sadeh LLC is Investigating Whether Terns Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

March 25, 2026

From Halper Sadeh LLC

Via Business Wire

Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)

March 25, 2026

From Terns Pharmaceuticals, Inc.

Via GlobeNewswire

As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors? ↗

March 23, 2026

Via The Motley Fool

This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain ↗

March 18, 2026

Via The Motley Fool

Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet? ↗

March 18, 2026

Via The Motley Fool

This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names ↗

March 18, 2026

Via The Motley Fool

This Biotech Fund Sold $8 Million of Terns Stock Last Quarter, but Here's Why It Still Seems Very Bullish ↗

March 18, 2026

Via The Motley Fool

This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally ↗

March 16, 2026

Via The Motley Fool

This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally ↗

March 16, 2026

Via The Motley Fool

Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing ↗

March 05, 2026

Via The Motley Fool

Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences

February 25, 2026

From Terns Pharmaceuticals, Inc.

Via GlobeNewswire

ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing ↗

February 20, 2026

Via The Motley Fool

Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge ↗

February 17, 2026

Via The Motley Fool

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

February 02, 2026

From Terns Pharmaceuticals, Inc.

Via GlobeNewswire

Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference

January 07, 2026

From Terns Pharmaceuticals, Inc.

Via GlobeNewswire

Stay updated with the stocks that are on the move in today's after-hours session. ↗

January 02, 2026

Via Chartmill

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

January 02, 2026

From Terns Pharmaceuticals, Inc.

Via GlobeNewswire

Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

December 11, 2025

From Terns Pharmaceuticals, Inc.

Via GlobeNewswire

Terns Announces Pricing of Upsized $650 Million Public Offering

December 09, 2025

From Terns Pharmaceuticals, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Terns Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Terns Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Terns Pharmaceuticals, Inc. - Common Stock trade on?

Terns Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Terns Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Terns Pharmaceuticals, Inc. - Common Stock is TERN on the Nasdaq Stock Market

What is the current price of Terns Pharmaceuticals, Inc. - Common Stock?

The current price of Terns Pharmaceuticals, Inc. - Common Stock is 52.72

When was Terns Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Terns Pharmaceuticals, Inc. - Common Stock was at 04/02/26 04:00 PM ET

What is the market capitalization of Terns Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Terns Pharmaceuticals, Inc. - Common Stock is 3.22B

How many shares of Terns Pharmaceuticals, Inc. - Common Stock are outstanding?

Terns Pharmaceuticals, Inc. - Common Stock has 3B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.